BMS Reports $635M Revenue from Two CAR-T Therapies in First Three Quarters of 2023, Up 62.8% Year-over-Year
Bristol-Myers Squibb
Biopharmaceutical and Nutritional Product R&D and Sales
Disclaimer: Due to limited proficiency, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article is only an introduction to medical and health-related drugs, not a recommendation of treatment options (if involved); this article does not constitute any investment advice.
October 26,HundredBristol-Myers Squibb (BMS) announced its Q3 2023 financial report: revenue of $11 billion, a year-over-year decrease of 2%.The reason is the decline in Revlimid sales, as generic versions of the drug entered the U.S. market in 2022.Mature products (In-Line) revenue was $8.3 billion, increasing 3% year over year.New Product Portfolio revenue was $928 million, representing a 68% increase year-over-year.
In the new product, BMS'sTwo CAR-T Therapies, Abecma and Breyanzi, Report Combined Q3 Revenue of $185 Million。Among whichThe revenue of CAR-T therapy Abecma was $93 million, a year-on-year decrease of 14%.Breyanzi Revenue of $92 Million。2023Q2 Abecma、Breyanzi, respectivelyRevenue of $132 million,$100 million,2023Q1Abecma、Breyanzi SeparatelyRevenue$147 million,$71 million.2023First three quartersTwo therapies in totalRevenue 6.35Billion US dollars, an increase of 62.8% year-on-year.2022Year-roundAbecma and Breyanzi generated revenues of $388 million and $182 million, respectively.
In addition,Its PD-1 monoclonal antibody Opdivo (commonly known as "O drug") 2023 Q3 revenue23billion US dollars, a year-on-year increase of 11%,Q1 revenue of $2.202 billion, Q2 revenue of $2.145 billion,Total revenue reached $8.249 billion in 2022, and this year is expected to surpass the total revenue of 2022.
1
Abecma
Time to Market:Approved for marketing in the United States in March 2021, granted conditional approval in Europe in June 2021, and approved for marketing in Japan in January 2022.
Indications:Relapsed or Refractory Multiple Myeloma
Abecma, jointly developed by Bristol-Myers Squibb (BMS) and Bluebird, is one of the three CAR-T therapies approved for the treatment of relapsed/refractory multiple myeloma. It is the world's first BCMA-targeted CAR-T cell therapy and the fifth CAR-T therapy approved by the FDA.
2
Breyanzi
Time to Market:Approved for marketing by the FDA in February 2021
Indications:Relapsed or Refractory Large B-Cell Lymphoma
Breyanzi is a CD19-directed CAR T-cell therapy with a 4-1BB co-stimulatory domain, which enhances the expansion and persistence of CAR T-cells. Breyanzi is manufactured from the patient’s own T-cells, which are collected and genetically re-engineered into CAR T-cells, followed by a one-time infusion treatment.
The approval of Breyanzi marks a milestone for Bristol-Myers Squibb in the field of cellular immunotherapy. The drug was acquired by BMS when it purchased Celgene for $74 billion in 2019.
